MDxHealth SA (MDXH) Prices 3.75M ADS IPO at $12/sh

MDxHealth SA (Nasdaq: MDXH), a commercial-stage precision diagnostics company, today announced the pricing of its initial public offering in the United States (the "Offering") of 3,750,000 American Depositary Shares (each representing 10 ordinary shares of the Company with no nominal value per share) ("ADSs") at a price to the public of USD 12.00 per ADS1 for total gross proceeds of USD 45.0 million2 before deducting underwriting discounts and commissions and estimated offering expenses.

In connection with the Offering, MDxHealth has granted the underwriters a 30-day option to purchase additional ordinary shares, which may be in the form of ADSs, on the same terms and conditions, representing up to 15% of the total number of ordinary shares (as the case may be, in the form of ADSs) offered in the Offering.

The closing of the Offering is expected to occur on November 8, 2021, subject to the satisfaction of customary closing conditions.

MDxHealth’s ordinary shares are currently listed on Euronext Brussels under the symbol “MDXH”. The ADSs are expected to begin trading on the NASDAQ Capital Market on November 4, 2021 under the symbol “MDXH”.

Piper Sandler and Oppenheimer & Co. Inc. are acting as lead book-running managers, BTIG is acting as a lead manager, and KBC Securities USA is acting as a co-manager for the Offering.

A registration statement on Form F-1 relating to and describing the terms of the Offering was filed with the U.S. Securities and Exchange Commission and was declared effective on November 3, 2021. The ADSs may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or a solicitation of an offer to buy securities of the Company nor shall there be any offer, solicitation or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification or publication of an offering prospectus under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities, if at all, has been or will be made in accordance with the registration requirements of the United States Securities Act of 1933 and the European Prospectus Regulation (Regulation (EU) 2017/1129), as relevant.

The Offering has been made only by means of a prospectus. When available, copies of the final prospectus relating to the Offering can be obtained from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by e-mail at [email protected], or by phone at (800) 747-3924 or Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, by e-mail at [email protected], or by phone at (212) 667-8055

You May Also Be Interested In

• MDxHealth SA (MDXH) PT Lowered to $2 at BTIG
• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• Citigroup set to join top banks in Anthropic IPO - Bloomberg